Azuma, Arata

Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 4,654

Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline

Raghu, G., Remy-Jardin, M., Myers, J. L., Richeldi, L., Ryerson, C. J., Lederer, D. J., Behr, J., Cottin, V., Danoff, S. K., Morell, F., et al. (2018) · American Journal of Respiratory and Critical Care Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisOccupational and environmental lung diseases

Cited by 4,103

An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis: An Update of the 2011 Clinical Practice Guideline

Raghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A. C., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., et al. (2015) · American Journal of Respiratory and Critical Care Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 1,916

Nintedanib for systemic sclerosis–associated interstitial lung disease

Distler, O., Highland, K. B., Gahlemann, M., Azuma, A., Fischer, A., Mayes, M. D., Raghu, G., Sauter, W., Girard, M., Alves, M., et al. (2019) · New England Journal of Medicine

Systemic Sclerosis and Related DiseasesInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Cited by 1,647

Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis.

Richeldi, L., Azuma, A., Cottin, V., Kreuter, M., Maher, T. M., Martinez, F. J., Oldham, J. M., Valenzuela, C., Clerisme-Beaty, E., Gordat, M., et al. (2025) · New England Journal of Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPulmonary Hypertension Research and Treatments

Cited by 297

Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS

Costabel, U., Inoue, Y., Richeldi, L., Collard, H. R., Tschoepe, I., Stowasser, S., & Azuma, A. (2016) · American Journal of Respiratory and Critical Care Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 280

Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis

Richeldi, L., Azuma, A., Cottin, V., Hesslinger, C., Stowasser, S., Valenzuela, C., Wijsenbeek, M. S., Zoz, D. F., Voss, F., & Maher, T. M. (2022) · New England Journal of Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPhosphodiesterase function and regulation

Cited by 236

Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis

Ogura, T., Taniguchi, H., Azuma, A., Inoue, Y., Kondoh, Y., Hasegawa, Y., Bando, M., Abe, S., Mochizuki, Y., Chida, K., et al. (2015) · European Respiratory Journal

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 215

Exacerbation of Idiopathic Interstitial Pneumonias Associated with Lung Cancer Therapy

Minegishi, Y., Takenaka, K., Mizutani, H., Sudoh, J., Noro, R., Okano, T., Azuma, A., Yoshimura, A., Ando, M., Tsuboi, E., et al. (2009) · Internal Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisLung Cancer Diagnosis and Treatment

Cited by 128

Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study

Cottin, V., Koschel, D., Günther, A., Albera, C., Azuma, A., Sköld, C. M., Tomassetti, S., Hormel, P., Stauffer, J. L., Strombom, I., et al. (2018) · ERJ Open Research

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPharmacovigilance and Adverse Drug Reactions

Cited by 121

Disruption of Nrf2 enhances susceptibility to airway inflammatory responses induced by low-dose diesel exhaust particles in mice

Li, Y. J., Takizawa, H., Azuma, A., Kohyama, T., Yamauchi, Y., Takahashi, S., Yamamoto, M., Kawada, T., Kudoh, S., & Sugawara, I. (2008) · Clinical Immunology

Asthma and respiratory diseasesAir Quality and Health Impacts

Cited by 70

Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan

Pirfenidone Clinical Study Group in Japan, Ikeda, K., Chiba, H., Nishikiori, H., Azuma, A., Kondoh, Y., Ogura, T., Taguchi, Y., Ebina, M., Sakaguchi, H., et al. (2020) · Respiratory Research

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 36

Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD)

Maher, T. M., Assassi, S., Azuma, A., Cottin, V., Hoffmann-Vold, A.-M., Kreuter, M., Oldham, J. M., Richeldi, L., Valenzuela, C., Wijsenbeek, M. S., et al. (2023) · BMJ Open Respiratory Research

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPulmonary Hypertension Research and Treatments

Cited by 28

Exploratory phase 2 study of the novel oral multi-kinase inhibitor TAS-115 in patients with idiopathic pulmonary fibrosis

Nishioka, Y., Homma, S., Ogura, T., Sato, S., Arai, N., Tomii, K., Kamio, K., Sakamoto, S., Miyazaki, Y., Tomioka, H., et al. (2023) · Respiratory Investigation

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPulmonary Hypertension Research and Treatments

Cited by 12

Japanese guidelines for the treatment of idiopathic pulmonary fibrosis 2023:Revised edition

Bando, M., Homma, S., Date, H., Kishi, K., Yamauchi, H., Sakamoto, S., Miyamoto, A., Goto, Y., Nakayama, T., Azuma, A., et al. (2024) · Respiratory Investigation

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPulmonary Hypertension Research and Treatments

Cited by 12